Filipe A Moura, MD, PhD
he/him/his
Assistant ProfessorCards
About
Research
Publications
2025
Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial.
Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Kang YM, Murphy SA, Zhang S, Lu MT, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS. Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial. Am Heart J 2025 PMID: 40081744, DOI: 10.1016/j.ahj.2025.02.022.Peer-Reviewed Original ResearchDesign and Rationale of the CORE -TIMI 72a and CORE2 -TIMI 72b Trials of Olezarsen in Patients with Severe Hypertriglyceridemia.
Marston NA, Bergmark BA, Alexander VJ, Karwatowska-Prokopczuk E, Kang YM, Moura FA, Prohaska TA, Zimerman A, Zhang S, Murphy SA, Tsimikas S, Giugliano RP, Sabatine MS. Design and Rationale of the CORE -TIMI 72a and CORE2 -TIMI 72b Trials of Olezarsen in Patients with Severe Hypertriglyceridemia. Am Heart J 2025 PMID: 40064331, DOI: 10.1016/j.ahj.2025.03.003.Peer-Reviewed Original ResearchIdentification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities.
Loesch DP, Garg M, Matelska D, Vitsios D, Jiang X, Ritchie SC, Sun BB, Runz H, Whelan CD, Holman RR, Mentz RJ, Moura FA, Wiviott SD, Sabatine MS, Udler MS, Gause-Nilsson IA, Petrovski S, Oscarsson J, Nag A, Paul DS, Inouye M. Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities. Nat Commun 2025, 16: 2124. PMID: 40032831, DOI: 10.1038/s41467-025-56695-z.Peer-Reviewed Original ResearchA Bayesian Interpretation of CABANA and Other Randomized Controlled Trials for Catheter Ablation in Patients With Atrial Fibrillation.
Nogueira A, Felix N, Kalil F, Tramujas L, Godoi A, Miyawaki IA, Bellavia A, Moura FA, Cardoso R, d'Avila A, Fernandes GC. A Bayesian Interpretation of CABANA and Other Randomized Controlled Trials for Catheter Ablation in Patients With Atrial Fibrillation. J Cardiovasc Electrophysiol 2025, 36: 617-624. PMID: 39834105, DOI: 10.1111/jce.16552.Peer-Reviewed Original ResearchSkeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes
do A H Souza A, Troschel A, Marquardt J, Hadžić I, Foldyna B, Moura F, Hainer J, Divakaran S, Blankstein R, Dorbala S, Di Carli M, Aerts H, Lu M, Fintelmann F, Taqueti V. Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes. European Heart Journal 2025, ehae827. PMID: 39827905, DOI: 10.1093/eurheartj/ehae827.Peer-Reviewed Original ResearchCoronary microvascular dysfunctionBody mass indexCoronary flow reserveIntermuscular adipose tissueSubcutaneous adipose tissueHeart failureFat infiltrationMarker of coronary microvascular dysfunctionPreserved left ventricular ejection fractionCardiovascular outcomesAssociated with coronary microvascular dysfunctionHigher IMATIncreased IMATPresence of coronary microvascular dysfunctionSkeletal muscleFlow reserveIncreased risk of MACEMyocardial infarctionStress positron emission tomographyAssociated with increased MACERisk of heart failureLow coronary flow reserveThoracic vertebra levelVentricular ejection fractionIntermuscular adipose tissue area
2024
Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
Carmo H, Castillo A, Bonilha I, Gomes E, Barreto J, Moura F, Davanzo G, de Brito Monteiro L, Muraro S, de Souza G, Morari J, Galdino F, Brunetti N, Reis-de-Oliveira G, Carregari V, Nadruz W, Martins-de-Souza D, Farias A, Velloso L, Proenca-Modena J, Mori M, Loh W, Bhatt D, Yellon D, Davidson S, De Oliveira P, Moraes-Vieira P, Sposito A. Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study. Frontiers In Pharmacology 2024, 15: 1402032. PMID: 39434905, PMCID: PMC11491754, DOI: 10.3389/fphar.2024.1402032.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsSARS-CoV-2 infectionSARS-CoV-2Viral replicationInflammatory responseInflammasome activationMarkers of inflammasome activationPlacebo-controlled studySuppress viral replicationBlood mononuclear cellsInfection in vitroPrimary metabolitesCOVID-19 patientsDouble-blindPrimary endpointHealthy volunteersSevere acute respiratory syndrome coronavirus 2Plasma markersAcute respiratory syndrome coronavirus 2Mononuclear cellsClinical trialsRespiratory syndrome coronavirus 2Day 2Syndrome coronavirus 2Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
Moura F, Bellavia A, Berg D, Melloni G, Feinberg M, Leiter L, Bohula E, Morrow D, Scirica B, Wiviott S, Sabatine M. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes Obesity And Metabolism 2024, 26: 4441-4449. PMID: 39056220, PMCID: PMC11410501, DOI: 10.1111/dom.15798.Peer-Reviewed Original ResearchNew-onset diabetesRisk of new-onset diabetesClinical risk modelWeight loss therapyRisk groupsWeight loss pharmacotherapyMultivariate Cox regressionStable cardiovascular patientsTherapeutic decision makingAbsolute risk reductionHigh-risk groupType 2 diabetesIndependent predictorsValidation cohortFollow-upPersonalized patient careCox regressionHazard ratioPrimary outcomeRisk modelHigh riskInterquartile rangePatientsDiabetesCardiovascular patients1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58
MI KANG Y, MELLONI G, CAHN A, RAZ I, MOURA F, BHATT D, INZUCCHI S, LEITER L, MCGUIRE D, WILDING J, GAUSE-NILSSON I, OSCARSSON J, MARSTON N, RUFF C, SABATINE M, WIVIOTT S. 1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58. Diabetes 2024, 73 DOI: 10.2337/db24-1896-lb.Peer-Reviewed Original ResearchDuke Clinical Research InstituteC-pepClinical Research InstituteDKA eventsC-peptideLower fasting C-peptideMedian follow-upRandomized to dapagliflozinFasting C-peptideDuration of T2DC-peptide testingRisk of DKACV outcome trialsAmerican College of CardiologyAbsolute risk differenceRate of DKAImpaired insulin secretionType 2 diabetesPlacebo armClinical featuresPopulation Health Research InstituteCSL BehringDiabetic ketoacidosisFerring PharmaceuticalsOutcome trials1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58
MI KANG Y, MELLONI G, CAHN A, RAZ I, MOURA F, BHATT D, INZUCCHI S, LEITER L, MCGUIRE D, WILDING J, GAUSE-NILSSON I, OSCARSSON J, MARSTON N, RUFF C, SABATINE M, WIVIOTT S. 1895-LB: Fasting C-Peptide and Type 1 Diabetes Polygenic Score Predict Diabetic Ketoacidosis in People with Type 2 Diabetes in DECLARE-TIMI 58. Diabetes 2024, 73 DOI: 10.2337/db24-1895-lb.Peer-Reviewed Original ResearchRisk of DKADuke Clinical Research InstituteC-pepC-peptidePolygenic scoresClinical Research InstitutePopulation Health Research InstituteHigh-risk ptsFasting C-peptideHealth Research InstituteCV outcome trialsAmerican College of CardiologyHigher-risk groupsPredicting DKAType 2 diabetesCSL BehringDiabetic ketoacidosisFerring PharmaceuticalsBristol-Myers SquibbSt. Jude MedicalNon-HLAIncreased riskCleveland ClinicDapagliflozinAmerican CollegeOlezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Murphy S, Goodrich E, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal Of Medicine 2024, 390: 1770-1780. PMID: 38587249, DOI: 10.1056/nejmoa2402309.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolElevated cardiovascular riskLevels of triglyceridesTriglyceride levelsCardiovascular riskModerate hypertriglyceridemiaApolipoprotein BAdverse eventsNon-high-density lipoprotein (HDL) cholesterolLow-density lipoprotein (LDL) cholesterolBaseline to 6 monthsMedian triglyceride levelsRisk of adverse eventsLDL cholesterol levelsHigh cardiovascular riskTriglyceride-rich lipoproteinsApolipoprotein C-IIISevere hypertriglyceridemiaMedian ageTriglyceride loweringPlatelet abnormalitiesNo significant changesPlaceboPhase 2bPrimary outcome